OCLG SEC-arkiveringar - Oncologix Tech, Inc.- Årsredovisning, Fullmaktsutlåtande, prospekt

Grundläggande statistik

CIK

799694

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Oncologix Tech, Inc.

SEC Filings (Chronological Order)

Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.

August 23, 2017	15-12G	Oncologix Tech 2G 15-12G 1 form15-12g.htm U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C.20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 0-15482 ONCOLOGIX TECH, INC. (Name of Small Business Issuer as
February 22, 2017	PRER14C	Oncologix Tech 14C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION AMENDMENT NO. 1 Preliminary Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: [X] Preliminary Information Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) [ ] Definitive Information Statement ON
February 22, 2017	8-K	Current Report 8-K 1 form8-k.htm U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C.20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 7, 2016 ONCOLOGIX TECH, INC. (Name of Small Business Issuer as Specified in Its Charter) Nevada 0-15482 86-1006416 (State or other jurisdiction of incorporation or org
February 22, 2017	EX-99.1	CERTIFICATE OF DESIGNATION (PURSUANT TO NRS 78.1955) EX-99.1 2 ex99-1.htm Exhibit 99.1 CERTIFICATE OF DESIGNATION (PURSUANT TO NRS 78.1955) USE BLACK INK ONLY – DO NOT HIGHLIGHT ABOVE SPACE IS FOR OFFICE USE ONLY Certificate of Designation For Nevada Profit Corporations (Pursuant to NRS 78.1955) 1. Name of corporation: ONCOLOGIX TECH, INC. 2. By resolution of the board of directors pursuant to a provision in the articles of incorporation, this certi
January 20, 2017	PRE 14C	Oncologix Tech 14C PRE 14C 1 pre14c.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Preliminary Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: [X] Preliminary Information Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) [ ] Definitive Information Stateme
December 30, 2016	8-K	Current Report 8-K 1 form8-k.htm U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2016 ONCOLOGIX TECH, INC. (Name of Small Business Issuer as Specified in Its Charter) Nevada 0-15482 86-1006416 (State or other jurisdiction of incorporation or
December 30, 2016	EX-99.1	A Limited Liability Company 1450 Dorchester Drive • P.O. Box 12730 Alexandria, Louisiana 71301 (71315) Telephone (318) 442-9533 • Fax (318) 442-9532 Toll Free (800) 640-0349 Writer’s Email: aaronavglaw.net www.vglaw.net December 29, 2016 EX-99.1 2 ex99-1.htm VILAR & GREEN ATTORNEYS AT LAW Mark F. Vilar Aaron L. Green A Limited Liability Company 1450 Dorchester Drive • P.O. Box 12730 Alexandria, Louisiana 71301 (71315) Telephone (318) 442-9533 • Fax (318) 442-9532 Toll Free (800) 640-0349 Writer’s Email: aaronavglaw.net www.vglaw.net December 29, 2016 OF COUNSEL R. Christopher Nevils Loren M. Lampert Jerry W. Deason, Jr. Paul Boudr
December 2, 2016	EX-99.1	Oncologix Tech, INC. SERIES B CONVERTIBLE PREFERRED STOCK PURCHASE AGREEMENT AMENDMENT # 1 Oncologix Tech, INC. SERIES B CONVERTIBLE PREFERRED STOCK PURCHASE AGREEMENT AMENDMENT # 1 This Series B CONVERTIBLE Preferred Stock Purchase Agreement (the “Agreement”) Amendment # 1, is made and entered into as of November16, 2016, by and among Oncologix Tech, Inc., a Nevada Corporation (the “Company”), and Diversified Innovative Marketing Enterprise Ltd., a Georgia Corporation, “Purchaser”). Re
December 2, 2016	EX-99.2	LEWIS FAMILY GROUP FUND LP c/o The Schwarz Firm PLLC 954 Lexington Ave, Suite 261 New York, New York 10021 Exhibit 99.2 LEWIS FAMILY GROUP FUND LP c/o The Schwarz Firm PLLC 954 Lexington Ave, Suite 261 New York, New York 10021 November 23, 2016 Roy Wayne Erwin President and Chief Executive Officer Oncologix Tech, Inc. Amian Angels, Inc. Esteemcare Inc. 1604 West Pinhook Rd. #200 Lafayette, Louisiana 70508 Re: Second Modification Agreement Re Maturity Date Set Forth in Secured Convertible Promissory Not
December 2, 2016	8-K	Current Report 8-K 1 form8-k.htm U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 24, 2016 ONCOLOGIX TECH, INC. (Name of Small Business Issuer as Specified in Its Charter) Nevada 0-15482 86-1006416 (State or other jurisdiction of (Commission (I.R.
November 15, 2016	EX-99.3	SECURED CONVERTIBLE PROMISSORY NOTE NEITHER THIS NOTE NOR THE SECURITIES INTO WHICH THIS NOTE IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION IN RELIANCE, INTER ALIA, UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED, SOLD,TRANSFERRED OR ASSIGNED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT.
November 15, 2016	EX-99.2	ONCOLOGIX TECH, INC. SECURED PROMISSORY NOTE NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS INSTRUMENT NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS.
November 15, 2016	EX-99.4	LEWIS FAMILY GROUP FUND LP c/o The Schwarz Firm PLLC 954 Lexington Ave, Suite 261 New York, New York 10021 LEWIS FAMILY GROUP FUND LP c/o The Schwarz Firm PLLC 954 Lexington Ave, Suite 261 New York, New York 10021 September 21, 2016 Roy Wayne Erwin President and Chief Executive Officer Oncologix Tech, Inc.
November 15, 2016	EX-99.5	LEWIS FAMILY GROUP FUND LP c/o The Schwarz Firm PLLC 954 Lexington Ave, Suite 261 New York, New York 10021 EX-99.5 6 ex99-5.htm LEWIS FAMILY GROUP FUND LP c/o The Schwarz Firm PLLC 954 Lexington Ave, Suite 261 New York, New York 10021 October 26, 2016 Roy Wayne Erwin President and Chief Executive Officer Oncologix Tech, Inc. Amian Angels, Inc. Esteemcare Inc. 1604 West Pinhook Rd. #200 Lafayette, Louisiana 70508 Re: Second Modification Agreement Re Maturity Date Set Forth in Secured Convertible Promiss
November 15, 2016	EX-99.1	NOTICE OF DEFAULT-REQUEST TO CURE EX-99.1 2 ex99-1.htm November 11, 2016 Diversified Innovative Marketing Enterprise, Ltd.- (DIMEVC) Attention: Chief Executive Officer, Tony O. Beaton 2550 Akers Mill Road Atlanta, GA 30339’ NOTICE OF DEFAULT-REQUEST TO CURE Dear Mr. Beaton: Please be advised that you are currently in Default of the Series B, Convertible Preferred, Stock Purchase Agreement, dated August 31, 2016, for reasons includ
November 15, 2016	8-K	Current Report 8-K 1 form8-k.htm U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C.20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2016 ONCOLOGIX TECH, INC. (Name of Small Business Issuer as Specified in Its Charter) Nevada 0-15482 86-1006416 (State or other jurisdiction of incorporation or o
October 26, 2016	8-K	Current Report 8-K 1 form8-k.htm U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2016 ONCOLOGIX TECH, INC. (Name of Small Business Issuer as Specified in Its Charter) Nevada 0-15482 86-1006416 (State or other jurisdiction of (Commission (I.R.S
October 26, 2016	EX-99.2	Oncologix Tech, INC. SERIES B CONVERTIBLE PREFERRED STOCK PURCHASE AGREEMENT Exhibit 99.2 Oncologix Tech, INC. SERIES B CONVERTIBLE PREFERRED STOCK PURCHASE AGREEMENT This Series B CONVERTIBLE Preferred Stock Purchase Agreement (the ?Agreement?) is made and entered into as of August 31, 2016, by and among Oncologix Tech, Inc., a Nevada corporation (the ?Company?), and Diversified Innovative Marketing Enterprise Ltd., a Georgia Corporation, ?Purchaser?). Recitals Whereas, t
October 26, 2016	EX-99.1	Important: Read attached instructions before completing form. EX-99.1 2 ex99-1.htm Exhibit 99.1 BARBARA K. CEGAVSKE Secretary of State 202 North Carson Street Carson City, Nevada 89701-4201 (775) 684 5708 Website: www.nvsos.gov Important: Read attached instructions before completing form. ABOVE SPACE IS FOR OFFICE USE ONLY Certificate of Designation For Nevada Profit Corporations (Pursuant to NRS 78.1955) 1. Name of corporation: ONCOLOGIX TECH, INC. 2. By re
June 24, 2016	EX-99.4	SECOND REPLACEMENT PROMISSORY NOTE EXHIBIT 99.4 BY ACCEPTING THIS OBLIGATION, THE HOLDER REPRESENTS AND WARRANTS THAT IT IS NOT A UNITED STATES PERSON (OTHER THAN AN EXEMPT RECIPIENT DESCRIBED IN SEC 6049(B)(4) OF THE INTERNAL REVENUE CODE AND REGULATIONS THEREUNDER) AND THAT IT IS NOT ACTING FOR OR ON BEHALF OF A UNITED STATES PERSON (OTHER THAN AN EXEMPT RECIPIENT DESCRIBED IN SEC. 6049(8)(4) OF THE INTERNAL REVENUE CODE AND THE
June 24, 2016	EX-99.2	FIRST AMENDMENT TO SETTLEMENT AGREEMENT FIRST AMENDMENT TO SETTLEMENT AGREEMENT This FIRST AMENDMENT TO SETTLEMENT AGREEMENT (the “First Amendment”) is dated effective as of the day of February, 2016 (the “Effective Date”), by and between ONCOLOGIX TECH, INC.
June 24, 2016	EX-99.1	SETTLEMENT AGREEMENT EX-99.1 2 ex99-1.htm EXHIBIT 99.1 SETTLEMENT AGREEMENT This SETTLEMENT AGREEMENT (the “Agreement”) is dated effective as of the 8th day of February, 2016 (the “Effective Date”), by and between ONCOLOGIX TECH, INC., a Nevada corporation (the “Borrower”), AMIAN ANGELS, INC. (f/k/a Angels of Mercy, Inc.), a Louisiana corporation, DOTOLO RESEARCH CORPORATION, a Louisiana corporation, ESTEEMCARE, INC.,
June 24, 2016	8-K	Current Report U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2016 ONCOLOGIX TECH, INC. (Name of Small Business Issuer as Specified in Its Charter) Nevada 0-15482 86-1006416 (State or other jurisdiction of (Commission (I.R.S. Employer incorporat
June 24, 2016	EX-99.3	SECOND AMENDMENT TO SETTLEMENT AGREEMENT Exhibit 99.3 SECOND AMENDMENT TO SETTLEMENT AGREEMENT This SECOND AMENDMENT TO SETTLEMENT AGREEMENT (the ?Second Amendment?) is dated effective as of the 8th day of April, 2016 (the ?Effective Date?), by and between ONCOLOGIX TECH, INC., a Nevada corporation (the ?Borrower?), AMIAN ANGELS, INC. (f/k/a Angels of Mercy, Inc.), a Louisiana corporation, DOTOLO RESEARCH CORPORATION, a Louisiana corpora
December 1, 2015	NT 10-K	Oncologix Tech OCLGNT10K08302015 OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response.
August 10, 2015	10-Q/A	Quarterly Report - OCLG10QA05312015 10-Q/A 1 oclg10qa05312015.htm OCLG10QA05312015 U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Mark One) [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended May 31, 2015 [] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission Fi
July 20, 2015	10-Q	Quarterly Report - OCLG10Q05312015 U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended May 31, 2015 [] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission File Number 0-15482 ONCOLOGIX TECH, INC. (Name of S
July 15, 2015	NT 10-Q	Oncologix Tech OCLGNT10Q05312015 OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response.
April 14, 2015	10-Q	U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended February 28, 2015 [] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission File Number 0-15482 ONCOLOGIX TECH, INC. (Name
January 23, 2015	SC 13G/A	OCLG / Oncologix Tech, Inc. / Typenex Co-Investment, LLC - NONE Passive Investment SC 13G/A 1 doc1.htm NONE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 02)* Oncologix Tech, Inc. (OCLG) (Name of Issuer) Common stock, par value $.001 per share (Title of Class of Securities) 68230m209 (CUSIP Number) Calendar Year 2015 (Date of Event Which Requires Filing of this Statement) Check the ap
January 16, 2015	10-Q/A	U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended November 30, 2014 [] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission File Number 0-15482 ONCOLOGIX TECH, INC. (Name
January 16, 2015	10-Q	U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended November 30, 2014 [] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission File Number 0-15482 ONCOLOGIX TECH, INC. (Name
January 14, 2015	NT 10-Q	OCLG / Oncologix Tech, Inc. NT 10-Q - - OCLGNT10Q11302014 OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response.
January 13, 2015	8-K/A	Current Report 8-K/A 1 oclg8ka08012013.htm OCLG8KA08012013 U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C.20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2013 ONCOLOGIX TECH, INC. (Name of Small Business Issuer as Specified in Its Charter) Nevada 0-15482 86-1006416 (State or other jurisdict
December 15, 2014	EX-10.24	EXECUTIVE EMPLOYMENT AGREEMENT EX-10.24 3 oclg10ka08312014ex1024.htm EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.24 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT ("Agreement") is made and entered into as of July 16, 2014, by and between Oncologix Tech Inc, (Company), a company duly incorporated and validly existing under the laws of Nevada and Mr. Harold Halman ("Executive"), with principal office located at
December 15, 2014	EX-21	Subsidiaries of Oncologix Tech, Inc. Subsidiaries of Registrant Exhibit 21 Subsidiaries of Oncologix Tech, Inc. Subsidiaries of Registrant Subsidiary State of Incorporation or Jurisdiction Percent of Ownership of Oncologix Tech, Inc. Dotolo Research Corporation Louisiana 100% Amian Angels, Inc. Louisiana 100% Advanced Medical Products & Technologies, Inc. Nevada 90%
December 15, 2014	EX-99	CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 99 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the use, in the statement on Form 10K ofa Oncologix Tech, Inc.
December 15, 2014	10-K/A	U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A 10-K/A 1 oclg10ka08312014.htm OCLG10KA08312014 U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Mark One) [X] Annual report under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended August 31, 2014 [] Transition report under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Num
December 11, 2014	EX-21	Subsidiaries of Oncologix Tech, Inc. Subsidiaries of Registrant Exhibit 21 Subsidiaries of Oncologix Tech, Inc. Subsidiaries of Registrant Subsidiary State of Incorporation or Jurisdiction Percent of Ownership of Oncologix Tech, Inc. Dotolo Research Corporation Louisiana 100% Amian Angels, Inc. Louisiana 100% Advanced Medical Products & Technologies, Inc. Nevada 90%
December 11, 2014	EX-99	Consent of Independent Registered Public Accounting Firm Exhibit 99 Consent of Independent Registered Public Accounting Firm Oncologix Tech, Inc.
December 11, 2014	10-K	U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K 10-K 1 oclg10k08312014.htm OCLG10K08312014 U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] Annual report under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended August 31, 2014 [] Transition report under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 0
December 11, 2014	EX-10.24	EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.24 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT ("Agreement") is made and entered into as of July 16, 2014, by and between Oncologix Tech Inc, (Company), a company duly incorporated and validly existing under the laws of Nevada and Mr. Harold Halman ("Executive"), with principal office located at 2640 West Adventure Court Anthem Arizona 85086 RECITALS A. WHEREAS, t
December 1, 2014	NT 10-K	OCLG / Oncologix Tech, Inc. NT 10-K - - OCLGNT10K08312014 NT 10-K 1 oclgnt10k08312014.htm OCLGNT10K08312014 UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0058 Washington, D.C. 20549 Expires: August 31, 2015 FORM 12b-25 Estimated average burden hours per response. . .2.50 NOTIFICATION OF LATE FILING 0-15452 68230M100 (Check One): [ X]Form 10-K[ ] Form 20-F Form 11-K [ ]Form 10-Q Form N-SAR Form N-CSR For Period Ended: Augu
October 2, 2014	8-K	Current Report 8-K 1 oclg8k09252014.htm OCLG8K09252014 U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 25, 2014 ONCOLOGIX TECH, INC. (Name of Small Business Issuer as Specified in Its Charter) Nevada 0-15482 86-1006416 (State or other jurisdicti
October 2, 2014	EX-10.3	PROMISSORY NOTE Exhibit 10.3 PROMISSORY NOTE September 25, 2014 Principal Amount Lafayette, Louisianna $75,000.00 FOR VALUE RECEIVED, ONCOLOGIX TECH, INC., a Nevada corporation (“Buyer”), by this Promissory Note (this “Note”), hereby promises to pay to Madhu Mathew Mammen, a resident of South Carolina (“Seller”), the aggregate principal sum of Seventy-Five Thousand and 00/100 Dollars ($75,000.00), together with i
October 2, 2014	EX-10.1	AMENDMENT NO. 1 TO SENIOR SECURED REVOLVING CREDIT FACILITY AGREEMENT IN THE AMOUNT OF US$4,000,000 BY AND AMONG ONCOLOGIX TECH, INC., as Borrower, AMIAN ANGELS, INC., DOTOLO RESEARCH CORPORATION, ESTEEMCARE INC., AFFORDABLE MEDICAL EQUIPMENT SOLUTIO Exhibit 10.1 AMENDMENT NO. 1 TO SENIOR SECURED REVOLVING CREDIT FACILITY AGREEMENT IN THE AMOUNT OF US$4,000,000 BY AND AMONG ONCOLOGIX TECH, INC., as Borrower, AMIAN ANGELS, INC., DOTOLO RESEARCH CORPORATION, ESTEEMCARE INC., AFFORDABLE MEDICAL EQUIPMENT SOLUTIONS, INC., as Joint and Several Guarantors, AND TCA GLOBAL CREDIT MASTER FUND, .LP, as Lender September 25, 2014 AMENDMENT NO. 1 TO SENIOR
October 2, 2014	EX-10.2	STOCK PURCHASE AGREEMENT by and among ONCOLOGIX TECH, INC. MADHU MATHEW MAMMEN IMAD SIDDIQUI ESTEEMCARE, INC. SEPTEMBER 25, 2014 STOCK PURCHASE AGREEMENT EX-10.2 3 oclg8k09252014ex102.htm OCLG8K09252014EX102 Exhibit 10.2 STOCK PURCHASE AGREEMENT by and among ONCOLOGIX TECH, INC. MADHU MATHEW MAMMEN IMAD SIDDIQUI and ESTEEMCARE, INC. SEPTEMBER 25, 2014 STOCK PURCHASE AGREEMENT THIS STOCK PURCHASE AGREEMENT (this “Agreement”), dated as of September 25, 2014, is made and entered into by and among Oncologix Tech, Inc., a Nevada corporation (the “Purcha
September 30, 2014	EX-3.9	Certificate of Designation For Nevada Profit Corporations (Pursuant to NRS 78.1955) EX-3.9 7 oclg10ka08312013ex39.htm ROSS MILLER Exhibit 3.9 ROSS MILLER Secretary of State 204 North Carson Street, Suite 1 Carson City, Nevada 89701-4520 (775) 684 5708 Website: www.nvsos.gov CERTIFICATE OF DESIGNATION (PURSUANT TO NRS 78.1955) Important: Read attached instructions before completing form. ABOVE SPACE IS FOR OFFICE USE ONLY Certificate of Designation For Nevada Profit Corporations (
September 30, 2014	EX-21	Subsidiaries of Oncologix Tech, Inc. Subsidiaries of Registrant EX-21 2 oclg10ka08312013ex21.htm SUBSIDIARIES OF ONCOLOGIX TECH, INC. Exhibit 21 Subsidiaries of Oncologix Tech, Inc. Subsidiaries of Registrant Subsidiary State of Incorporation or Jurisdiction Percent of Ownership of Oncologix Tech, Inc. Dotolo Research Corporation Louisiana 100% Angels of Mercy, Inc. Louisiana 100% Oncologix Corporation Nevada 90% International Environment Corporation Delaware
September 30, 2014	EX-10.23	EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.23 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT ("Agreement") is made and entered into as of July 31, 2013, by and between Oncologix Tech, Inc. (Company), a company duly incorporated and validly existing under the laws of Nevada and Vickie G. Hart ("Executive"), with principal office located at 212 Edgewood Drive, Pineville, Louisiana 71360. RECITALS A. WHEREAS, th
September 30, 2014	10-K/A	U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Mark One) [X] Annual report under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended August 31, 2013 [] Transition report under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 0-15482 ONCOLOGIX TECH, INC. (Name of smal
September 30, 2014	EX-10.22	EXECUTIVE EMPLOYMENT AGREEMENT EX-10.22 8 oclg10ka08312013ex1022.htm EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.22 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT ("Agreement") is made and entered into as of April 2, 2013, by and between Oncologix Tech, Inc. (Company), a company duly incorporated and validly existing under the laws of Nevada and Michael A. Kramarz ("Executive"), with principal office located a
July 31, 2014	EX-10.22	EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.22 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT ("Agreement") is made and entered into as of April 2, 2013, by and between Oncologix Tech, Inc. (Company), a company duly incorporated and validly existing under the laws of Nevada and Michael A. Kramarz ("Executive"), with principal office located at 206 Crown St. SW, Wyoming, MI 49548. RECITALS A. WHEREAS, the Compa
July 31, 2014	EX-21	Subsidiaries of Oncologix Tech, Inc. Subsidiaries of Registrant Exhibit 21 Subsidiaries of Oncologix Tech, Inc. Subsidiaries of Registrant Subsidiary State of Incorporation or Jurisdiction Percent of Ownership of Oncologix Tech, Inc. Dotolo Research Corporation Louisiana 100% Angels of Mercy, Inc. Louisiana 100% Oncologix Corporation Nevada 90% International Environment Corporation Delaware 100% Interpretel (Canada) Inc. Province of Ontario 100% Interpretel, I
July 31, 2014	10-Q/A	U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Mark One) [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended November 30, 2013. [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission File Number 0-15482 ONCOLOGIX TECH, INC. (
July 31, 2014	EX-3.9	Certificate of Designation For Nevada Profit Corporations (Pursuant to NRS 78.1955) Exhibit 3.9 ROSS MILLER Secretary of State 204 North Carson Street, Suite 1 Carson City, Nevada 89701-4520 (775) 684 5708 Website: www.nvsos.gov CERTIFICATE OF DESIGNATION (PURSUANT TO NRS 78.1955) Important: Read attached instructions before completing form. ABOVE SPACE IS FOR OFFICE USE ONLY Certificate of Designation For Nevada Profit Corporations (Pursuant to NRS 78.1955) 1. Name of corporatio
July 31, 2014	10-K/A	U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Mark One) [X] Annual report under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended August 31, 2013 [] Transition report under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 0-15482 ONCOLOGIX TECH, INC. (Name of smal
July 31, 2014	EX-10.23	EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.23 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT ("Agreement") is made and entered into as of July 31, 2013, by and between Oncologix Tech, Inc. (Company), a company duly incorporated and validly existing under the laws of Nevada and Vickie G. Hart ("Executive"), with principal office located at 212 Edgewood Drive, Pineville, Louisiana 71360. RECITALS A. WHEREAS, th
July 22, 2014	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C.20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2014 ONCOLOGIX TECH, INC. (Name of Small Business Issuer as Specified in Its Charter) Nevada 0-15482 86-1006416 (State or other jurisdiction of incorporation or organization) (Commissi
July 15, 2014	10-Q	U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q 10-Q 1 oclg10q05312014.htm OCLG10Q05312014 U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended May 31, 2014 p TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission File Number
June 3, 2014	SC 13G/A	OCLG / Oncologix Tech, Inc. / Typenex Co-Investment, LLC - NONE Passive Investment SC 13G/A 1 doc1.htm NONE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 01)* Oncologix Tech, Inc. (OCLG) (Name of Issuer) Common stock, par value $.001 per share (Title of Class of Securities) 68230m209 (CUSIP Number) June 03, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropr
June 3, 2014	SC 13G	OCLG / Oncologix Tech, Inc. / Typenex Co-Investment, LLC - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* Oncologix Tech, Inc. (OCLG) (Name of Issuer) Common stock, par value $.001 per share (Title of Class of Securities) 68230m209 (CUSIP Number) June 03, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box t
May 28, 2014	8-K	Unregistered Sales of Equity Securities - OCLG8K05232014 U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C.20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2014 ONCOLOGIX TECH, INC. (Name of Small Business Issuer as Specified in Its Charter) Nevada 0-15482 86-1006416 (State or other jurisdiction of incorporation or organization) (Commissio
April 21, 2014	10-Q	U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended February 28, 2014 [] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission File Number 0-15482 ONCOLOGIX TECH, INC. (Name
April 14, 2014	NT 10-Q	- OCLGNT10Q02282014 NT 10-Q 1 oclgnt10q02282014.htm OCLGNT10Q02282014 UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0058 Washington, D.C. 20549 Expires: August 31, 2015 Estimated average burden FORM 12b-25 hours per response. . .2.50 NOTIFICATION OF LATE FILING 0-15452 68230M100 (Check One): [ ]Form 10-K [ ]Form 20-F [ ] Form 11-K [X]Form 10-Q [ ]Form N-SAR [ ]Form N-CSR For Period En
April 1, 2014	10-Q/A	U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Mark One) [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended November 30, 2013. [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission File Number 0-15482 ONCOLOGIX TECH, INC. (
April 1, 2014	EX-21	Subsidiaries of Oncologix Tech, Inc. Subsidiaries of Registrant Exhibit 21 Subsidiaries of Oncologix Tech, Inc. Subsidiaries of Registrant Subsidiary State of Incorporation or Jurisdiction Percent of Ownership of Oncologix Tech, Inc. Dotolo Research Corporation Louisiana 100% Angels of Mercy, Inc. Louisiana 100% Oncologix Corporation Nevada 90% International Environment Corporation Delaware 100% Interpretel (Canada) Inc. Province of Ontario 100% Interpretel, I
April 1, 2014	10-K/A	U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Mark One) [X] Annual report under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended August 31, 2013 [] Transition report under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 0-15482 ONCOLOGIX TECH, INC. (Name of smal
April 1, 2014	EX-10.22	EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.22 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT ("Agreement") is made and entered into as of April 2, 2013, by and between Oncologix Tech, Inc. (Company), a company duly incorporated and validly existing under the laws of Nevada and Michael A. Kramarz ("Executive"), with principal office located at 206 Crown St. SW, Wyoming, MI 49548. RECITALS A. WHEREAS, the Compa
April 1, 2014	EX-3.9	Certificate of Designation For Nevada Profit Corporations (Pursuant to NRS 78.1955) Exhibit 3.9 ROSS MILLER Secretary of State 204 North Carson Street, Suite 1 Carson City, Nevada 89701-4520 (775) 684 5708 Website: www.nvsos.gov CERTIFICATE OF DESIGNATION (PURSUANT TO NRS 78.1955) Important: Read attached instructions before completing form. ABOVE SPACE IS FOR OFFICE USE ONLY Certificate of Designation For Nevada Profit Corporations (Pursuant to NRS 78.1955) 1. Name of corporatio
April 1, 2014	EX-10.23	EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.23 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT ("Agreement") is made and entered into as of July 31, 2013, by and between Oncologix Tech, Inc. (Company), a company duly incorporated and validly existing under the laws of Nevada and Vickie G. Hart ("Executive"), with principal office located at 212 Edgewood Drive, Pineville, Louisiana 71360. RECITALS A. WHEREAS, th
February 10, 2014	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: November 30, 2013 o TRANSITION REPORT PURSUA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: November 30, 2013 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to ONCOLOGIX TECH, INC. (Exact name of registrant
February 7, 2014	DEF 14C	- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Definitive Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: o Preliminary Information Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) x Definitive Information Statement ONCOLOGIX TECH, INC. (Nam
January 28, 2014	PRE 14C	- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Preliminary Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: x Preliminary Information Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) o Definitive Information Statement ONCOLOGIX TECH, INC. (Na
January 16, 2014	10-Q	Oncologix Tech (Quarterly Report) 10-Q 1 oclg10q11302013.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: November 30, 2013 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to ONCOLOGIX TECH, INC. (
January 14, 2014	NT 10-Q	- UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0058 Washington, D.
January 8, 2014	8-K/A	Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2014 ONCOLOGIX TECH, INC. (Exact name of registrant as specified in its charter) Nevada 000-15482 86-1006416 (State or Other Jurisdiction (Commission (I.R.S. Employer of
January 8, 2014	EX-99.3	REVOLVING CONVERTIBLE PROMISSORY NOTE Exhibit 99.3 NEITHER THIS NOTE NOR THE SECURITIES THAT ARE ISSUABLE TO THE HOLDER UPON CONVERSION HEREOF (COLLECTIVELY, THE "SECURITIES") HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “1933 ACT”), OR THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION. NEITHER THE SECURITIES NOR ANY INTEREST OR PARTICIPATION THEREIN MAY BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED
January 8, 2014	8-K/A	Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2014 ONCOLOGIX TECH, INC. (Exact name of registrant as specified in its charter) Nevada 000-15482 86-1006416 (State or Other Jurisdiction (Commission (I.R.S. Employer of
January 8, 2014	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2014 ONCOLOGIX TECH, INC. (Exact name of registrant as specified in its charter) Nevada 000-15482 86-1006416 (State or Other Jurisdiction (Commission (I.R.S. Employer of In
January 8, 2014	EX-99.2	SENIOR SECURED REVOLVING CREDIT FACILITY AGREEMENT IN THE AMOUNT OF US$4,000,000 BY AND AMONG ONCOLOGIX TECH, INC., as Borrower, ANGELS OF MERCY, INC., DOTOLO RESEARCH CORPORATION, as Joint and Several Guarantors, TCA GLOBAL CREDIT MASTER FUND, LP, a Exhibit 99.2 SENIOR SECURED REVOLVING CREDIT FACILITY AGREEMENT IN THE AMOUNT OF US$4,000,000 BY AND AMONG ONCOLOGIX TECH, INC., as Borrower, ANGELS OF MERCY, INC., DOTOLO RESEARCH CORPORATION, as Joint and Several Guarantors, AND TCA GLOBAL CREDIT MASTER FUND, LP, as Lender November 30, 2013 SENIOR SECURED REVOLVING CREDIT FACILITY AGREEMENT This SENIOR SECURED REVOLVING CREDIT FACILITY AGREEMENT
January 8, 2014	EX-99.1	Oncologix Closes $4,000,000 Revolving Line Credit Facility from Senior Lender Exhibit 99.1 Oncologix Closes $4,000,000 Revolving Line Credit Facility from Senior Lender Alexandria, LA—January 8, 2014-Oncologix Tech Inc. (OTCQB:OCLG), announced today that it has closed on a $4,000,000 revolving line of credit facility. Under the terms of the agreement, TCA Global Credit Master Fund, L.P. (“TCA Global”) has committed to lend up to a total of $4,000,000 USD through one of the
December 19, 2013	EX-99	CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM EXHIBIT 99 SEALE AND BEERS, CPAs PCAOB & CPAB REGISTERED AUDITORS www.sealebeers.com CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the use, in the statement on Form 10K of Oncologix Tech, Inc. of our report dated December 16, 2013 on our audit of the financial statements of Oncologix Tech, Inc as of August 31, 2013, and the related statements of operations, stockholders? e
December 19, 2013	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: August 31, 2013 o TRANSITION REPORT PURSUANT TO SECT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: August 31, 2013 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to ONCOLOGIX TECH, INC. (Exact name of registrant as specifi
December 19, 2013	EX-21	Subsidiaries of Oncologix Tech, Inc. Subsidiaries of Registrant EXHIBIT 21 Subsidiaries of Oncologix Tech, Inc. Subsidiaries of Registrant Subsidiary State of Incorporation or Jurisdiction Percent of Ownership of Oncologix Tech, Inc. Dotolo Research Corporation Louisiana 100% Angels of Mercy, Inc. Louisiana 100% Oncologix Corporation Nevada 90% International Environment Corporation Delaware 100% Interpretel (Canada) Inc. Province of Ontario 100% Interpretel, I
December 17, 2013	8-K	- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2013 ONCOLOGIX TECH, INC. (Exact name of registrant as specified in its charter) Nevada 000-15482 86-1006416 (State or Other Jurisdiction (Commission (I.R.S. Employer of
December 17, 2013	EX-99.1	Oncologix Tech Acquires Amian Health Services; Gains Leading Veterans and Private Pay Healthcare Service Company Exhibit 99.1 Oncologix Tech Acquires Amian Health Services; Gains Leading Veterans and Private Pay Healthcare Service Company ALEXANDRIA, LA, December 17, 2013 – Oncologix Tech Inc. (OTCQB: OCLG), announced today the Company has purchased the assets of Amian Health Services, a leader in the Personal Care Attendant (PCA) healthcare services industry for Veterans and Private Pay clients. Wayne Erwin
December 16, 2013	EX-21	Subsidiaries of Oncologix Tech, Inc. Subsidiaries of Registrant EXHIBIT 21 Subsidiaries of Oncologix Tech, Inc. Subsidiaries of Registrant Subsidiary State of Incorporation or Jurisdiction Percent of Ownership of Oncologix Tech, Inc. Dotolo Research Corporation Louisiana 100% Angels of Mercy, Inc. Louisiana 100% Oncologix Corporation Nevada 90% International Environment Corporation Delaware 100% Interpretel (Canada) Inc. Province of Ontario 100% Interpretel, I
December 16, 2013	EX-99	CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM EXHIBIT 99 SEALE AND BEERS, CPAs PCAOB & CPAB REGISTERED AUDITORS www.sealebeers.com CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the use, in the statement on Form 10K of Oncologix Tech, Inc. of our report dated December 16, 2013 on our audit of the financial statements of Oncologix Tech, Inc as of August 31, 2013, and the related statements of operations, stockholders? e
December 16, 2013	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: August 31, 2013 o TRANSITION REPORT PURSUANT TO SECTIO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: August 31, 2013 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to ONCOLOGIX TECH, INC. (Exact name of registrant as specified
November 27, 2013	NT 10-K	- OCLGNT10K08312013 UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0058 Washington, D.
August 7, 2013	8-K	Financial Statements and Exhibits U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C.20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2013 ONCOLOGIX TECH, INC. (Name of Small Business Issuer as Specified in Its Charter) Nevada 0-15482 86-1006416 86-1006416 (State or Other Jurisdiction (Commission (I.R.S. Employer of
July 22, 2013	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: May 31, 2013 o TRANSITION REPORT PURSUANT TO S 10-Q 1 oclg10q05312013.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: May 31, 2013 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to ONCOLOGIX TECH, INC. (Name
July 15, 2013	NT 10-Q	- OCLGNT10Q05312013 UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0058 Washington, D.
May 28, 2013	S-8	- As filed with the Securities and Exchange Commission on May 22, 2013 Registration No.
May 28, 2013	EX-4	ONCOLOGIX TECH, INC. 2013 OMNIBUS INCENTIVE PLAN EFFECTIVE May 20, 2013 ONCOLOGIX TECH, INC. 2013 Omnibus Incentive Plan TABLE OF CONTENTS Exhibit 4.1 ONCOLOGIX TECH, INC. 2013 OMNIBUS INCENTIVE PLAN EFFECTIVE May 20, 2013 ONCOLOGIX TECH, INC. 2013 Omnibus Incentive Plan TABLE OF CONTENTS Page I. Background 1 II. Purpose 1 III. Definitions 1 IV. Administration 9 4.01 Authority of the Committee 9 4.02 Manner of Exercise of Committee Authority 9 4.03 Advisors and Agents of the Committee 10 4.04 Records and Reports of the Committee 10 4
April 18, 2013	10-Q/A	U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Amendment No. 1) U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended February 28, 2013. [] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 0-15482 ONCOLO
April 15, 2013	10-Q	U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended February 28, 2013. [] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 0-15482 ONCOLOGIX TECH, INC. (Name
March 27, 2013	EX-10.2	EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.2 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT ("Agreement") is made and entered into as of March 15, 2013, by and between Oncologix, Tech, (Company), a company duly incorporated and validly existing under the laws of Nevada and Roy Wayne Erwin ("Executive"), with principal office located at 212 Edgewood Drive, Pineville, Louisiana, 71360. RECITALS A. WHEREAS, cont
March 27, 2013	EX-10.1	STOCK PURCHASE AGREEMENT Exhibit 10.1 STOCK PURCHASE AGREEMENT This STOCK PURCHASE AGREEMENT (the “Agreement”), dated as of March 22, 2013 by and among Clearview Medical, LLC, a Louisiana limited liability company, (“CM” or “Seller”) with a principal place of business at 212 Edgewood Drive, Pineville, Louisiana 71360, Oncologix Tech, Inc.(“OCLG”) a Nevada corporation, with a principal place of business in Grand Rapids, MI
March 27, 2013	8-K	Current Report U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C.20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2013 ONCOLOGIX TECH, INC. (Name of Small Business Issuer as Specified in Its Charter) Nevada 0-15482 86-1006416 (State or other jurisdiction of (Commission File Number) (I.R.S. Employ
March 25, 2013	8-K	Current Report 8-K 1 oncologix8k32212013.htm FORM 8-K U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C.20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2013 ONCOLOGIX TECH, INC. (Name of Small Business Issuer as Specified in Its Charter) Nevada 0-15482 86-1006416 (State or other jurisdiction of
January 14, 2013	10-Q	U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended November 30, 2012. [] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission File Number 0-15482 ONCOLOGIX TECH, INC. (Nam
January 9, 2013	8-K	Unregistered Sales of Equity Securities U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C.20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2013 ONCOLOGIX TECH, INC. (Name of Small Business Issuer as Specified in Its Charter) Nevada 0-15482 86-1006416 (State or other jurisdiction of (Commission File Number) (I.R.S. Emplo
December 7, 2012	EX-99	Consent of Independent Registered Public Accounting Firm Exhibit 99 Consent of Independent Registered Public Accounting Firm Oncologix Tech, Inc.
December 7, 2012	10-K	U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] Annual report under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended August 31, 2012 [] Transition report under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 0-15482 ONCOLOGIX TECH, INC. (Name of small
December 7, 2012	EX-21	Subsidiaries of Oncologix Tech, Inc. Subsidiaries of Registrant Exhibit 21 Subsidiaries of Oncologix Tech, Inc. Subsidiaries of Registrant Subsidiary State of Incorporation or Jurisdiction Percent of Ownership of Oncologix Tech, Inc. Oncologix Corporation Nevada 90% International Environment Corporation Delaware 100% Interpretel (Canada) Inc. Province of Ontario 100% Interpretel, Inc. Arizona 100% Telplex International Arizona 100%
November 29, 2012	NT 10-K	- FORM 12B25 OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response.
October 17, 2012	8-K	Unregistered Sales of Equity Securities - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2012 ONCOLOGIX TECH, INC (Exact name of registrant as specified in its charter) Nevada 000-15482 86-1006416 (State or Other Jurisdiction (Commission (I.R.S. Employer of In
July 16, 2012	10-Q	U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended May 31, 2012. ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission File Number 0-15482 ONCOLOGIX TECH, INC. (Name of Sma
April 16, 2012	10-Q	U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACE OF 1934. For the quarterly period ended February 29, 2012. [] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission File Number 0-15482 ONCOLOGIX TECH, INC. (Nam
January 27, 2012	8-K	Unregistered Sales of Equity Securities - FORM 8K U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C.20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2012 ONCOLOGIX TECH, INC. (Name of Small Business Issuer as Specified in Its Charter) Nevada 0-15482 86-1006416 (State or other jurisdiction of (Commission File Number) (I.R.S. Empl
January 13, 2012	10-Q	U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended November 30, 2011. o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission File Number 0-15482 ONCOLOGIX TECH, INC. (Name o
December 28, 2011	8-K	Unregistered Sales of Equity Securities 8-K 1 oncologix8k12262011.htm FORM 8-K U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C.20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 26, 2011 ONCOLOGIX TECH, INC. (Name of Small Business Issuer as Specified in Its Charter) Nevada 0-15482 86-1006416 (State or other jurisdiction
December 1, 2011	EX-21	Subsidiaries of Oncologix Tech, Inc. Subsidiaries of Registrant Exhibit 21 Subsidiaries of Oncologix Tech, Inc. Subsidiaries of Registrant Subsidiary State of Incorporation or Jurisdiction Percent of Ownership of BestNet Communications Corp. Oncologix Corporation Nevada 90% International Environment Corporation Delaware 100% Interpretel (Canada) Inc. Province of Ontario 100% Interpretel, Inc. Arizona 100% Telplex International Arizona 100%
December 1, 2011	10-K	U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K 10-K 1 oncologix8312011.htm FORM 10-K U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] Annual report under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended August 31, 2011 [] Transition report under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 0-1548
December 1, 2011	EX-99	Consent of Independent Registered Public Accounting Firm Exhibit 99 Consent of Independent Registered Public Accounting Firm Oncologix Tech, Inc.
November 29, 2011	NT 10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 OMB APPROVAL OMB Number: 3235-0058 Expires: May 31, 2012 Estimated average burden hours per response.
October 21, 2011	8-K	Unregistered Sales of Equity Securities U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C.20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 19, 2011 ONCOLOGIX TECH, INC. (Name of Small Business Issuer as Specified in Its Charter) Nevada 0-15482 86-1006416 (State or other jurisdiction of (Commission File Number) (I.R.S. Empl
October 11, 2011	8-K	Unregistered Sales of Equity Securities U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C.20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 6, 2011 ONCOLOGIX TECH, INC. (Name of Small Business Issuer as Specified in Its Charter) Nevada 0-15482 86-1006416 (State or other jurisdiction of (Commission File Number) (I.R.S. Emplo
July 15, 2011	10-Q	U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended May 31, 2011. o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission File Number 0-15482 ONCOLOGIX TECH, INC. (Name of Sma
July 11, 2011	8-K	Termination of a Material Definitive Agreement U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 6, 2011 ONCOLOGIX TECH, INC. (Name of Small Business Issuer as Specified in Its Charter) Nevada 0-15482 86-1006416 (State or other jurisdiction of (Commission File Number) (I.R.S. Employe
April 25, 2011	8-K/A	Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2010 ONCOLOGIX TECH, INC. (Name of Small Business Issuer as Specified in Its Charter) Nevada 0-15482 86-1006416 (State or other jurisdiction of (Commission File Number) (I.R.S.
April 22, 2011	CORRESP	April 25, 2011 April 25, 2011 Martin James Securities and Exchange Commission Division of Corporate Finance Mail Stop 3030 100 F Street, NW Washington D.
April 21, 2011	DEF 14C	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Definitive Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Definitive Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: [ ] Preliminary Information Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) [X] Definitive Information Statement ONCOLOGIX TECH, INC
April 13, 2011	10-Q	U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended February 28, 2011. o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission File Number 0-15482 ONCOLOGIX TECH, INC. (Name o
April 1, 2011	PRER14C	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Preliminary Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Preliminary Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: [X] Preliminary Information Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) [ ] Definitive Information Statement ONCOLOGIX TECH, IN
March 21, 2011	10-Q/A	U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Mark One) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended November 30, 2010. o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission File Number 0-15482 ONCOLOGIX TECH, INC. (Name
March 21, 2011	CORRESP	March 21, 2011 March 21, 2011 Jeff Jaramillo Securities and Exchange Commission Division of Corporate Finance Mail Stop 3030 100 F Street, NW Washington D.
March 21, 2011	10-Q/A	U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Mark One) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended May 31, 2010. o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT 0F 1934 For the transition period from to . Commission File Number 0-15482 ONCOLOGIX TECH, INC. (Name of Sm
March 21, 2011	10-Q/A	U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Mark One) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended November 30, 2009. o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission File Number 0-15482 ONCOLOGIX TECH, INC. (Name
March 21, 2011	10-Q/A	U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Mark One) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended February 28, 2010. o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission File Number 0-15482 ONCOLOGIX TECH, INC. (Name
March 10, 2011	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 DEF 14A 1 oncologixdef14a.htm DEFINITIVE PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission
March 9, 2011	CORRESP	March 07, 2011 CORRESP 1 filename1.htm March 07, 2011 Jeff Jaramillo Securities and Exchange Commission Division of Corporate Finance Mail Stop 3030 100 F Street, NW Washington D.C. 20549 RE: Oncologix Tech Inc. P.O. Box 8832 Grand Rapids, MI 49518-8832 Dear Mr. Jaramillo: We respond as follows to your letter of March 2, 2011. Amendment to Form 10-K for Fiscal Year Ended August 31, 2010, filed February 17, 2011
March 9, 2011	EX-99	Consent of Independent Registered Public Accounting Firm EXHIBIT 99 Consent of Independent Registered Public Accounting Firm Oncologix Tech, Inc.
March 9, 2011	10-Q/A	U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Mark One) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended February 28, 2010. o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission File Number 0-15482 ONCOLOGIX TECH, INC. (Name
March 9, 2011	10-Q/A	U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Mark One) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended November 30, 2009. o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission File Number 0-15482 ONCOLOGIX TECH, INC. (Name
March 9, 2011	10-Q/A	U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Mark One) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended May 31, 2010. o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT 0F 1934 For the transition period from to . Commission File Number 0-15482 ONCOLOGIX TECH, INC. (Name of Sm
March 9, 2011	10-Q/A	U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Mark One) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended November 30, 2010. o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission File Number 0-15482 ONCOLOGIX TECH, INC. (Name
March 9, 2011	EX-21	Subsidiaries of Oncologix Tech, Inc. Subsidiaries of Registrant Exhibit 21 Subsidiaries of Oncologix Tech, Inc. Subsidiaries of Registrant Subsidiary State of Incorporation or Jurisdiction Percent of Ownership of BestNet Communications Corp. Oncologix Corporation Nevada 100% International Environment Corporation Delaware 100% Interpretel (Canada) Inc. Province of Ontario 100% Interpretel, Inc. Arizona 100% Telplex International Arizona 100%
March 9, 2011	10-K/A	U. S. SECURITIES AND EXCHANGE COMMISSION U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Mark One) x Annual report under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended August 31, 2010 o Transition report under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 0-15482 ONCOLOGIX TECH, INC. (Name of small b
February 24, 2011	PRER14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [X] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [ ] Definitive P
February 22, 2011	PRER14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [X] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [ ] Definitive P
February 17, 2011	10-K/A	U. S. SECURITIES AND EXCHANGE COMMISSION 10-K/A 1 oncologix10k0831101.htm PERIOD ENDED 08-31-10 U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Mark One) x Annual report under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended August 31, 2010 o Transition report under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission Fil
February 17, 2011	EX-16.1	PCAOB Registered, Members of AACPA, CPCAF and UACPA & #160; EXHIBIT 16.1 CHISHOLM, BIERWOLF, NILSON & MORRILL, LLC Certified Public Accountants Phone (801) 292-8756 • Fax (801) 292-8809 • wwwcbnm.cpa.com Nephi J. Bierwolf Troy F. Nilson Douglas W. Morrill September 13, 2010 Office of the Chief Accountant Securities and Exchange Commission 450 West Fifth Street N.W. Washington DC 20549 Ladies and Gentlemen, We have read the statements about our firm
February 17, 2011	10-Q/A	U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Mark One) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended November 30, 2009. o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission File Number 0-15482 ONCOLOGIX TECH, INC. (Name
February 17, 2011	8-K/A	Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2010 ONCOLOGIX TECH, INC. (Name of Small Business Issuer as Specified in Its Charter) Nevada 0-15482 &# 160; 86-1006416 (State or other jurisdiction of (Commission File Number)
February 17, 2011	10-Q/A	U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Mark One) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended May 31, 2010. o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT 0F 1934 For the transition period from to . Commission File Number 0-15482 ONCOLOGIX TECH, INC. (Name of Sm
February 17, 2011	EX-99	Consent of Independent Registered Public Accounting Firm EXHIBIT 99 Consent of Independent Registered Public Accounting Firm Oncologix Tech, Inc.
February 17, 2011	CORRESP	CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 February 14, 2011 Andri Boerman Securities and Exchange Commission Division of Corporate Finance Mail Stop 3030 100 F Street, NW Washington D.
February 17, 2011	10-Q/A	U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Mark One) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended November 30, 2010. o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission File Number 0-15482 ONCOLOGIX TECH, INC. (Name
February 17, 2011	10-Q/A	U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Mark One) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended February 28, 2010. o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission File Number 0-15482 ONCOLOGIX TECH, INC. (Name
February 17, 2011	EX-21	Subsidiaries of Oncologix Tech, Inc. Subsidiaries of Registrant Exhibit 21 Subsidiaries of Oncologix Tech, Inc. Subsidiaries of Registrant Subsidiary State of Incorporation or Jurisdiction Percent of Ownership of BestNet Communications Corp. Oncologix Corporation Nevada 100% International Environment Corporation Delaware 100% Interpretel (Canada) Inc. Province of Ontario 100% Interpretel, Inc. Arizona 100% Telplex International Arizona 100%
February 11, 2011	EX-99.1	WATCHME PROFILE MEDIA SERVICES, INC. PRE-INCORPORATION AGREEMENT EXHIBIT 99.1 WATCHME PROFILE MEDIA SERVICES, INC. PRE-INCORPORATION AGREEMENT The parties to this Agreement are Oncologix Tech, Inc., a Nevada corporation registered under the Securities Exchange Act of 1934, as amended, having its principal place of business at P.O. Box 8832, Grand Rapids, MI 49318-8832 (?Oncologix?) and Melvin Brown, who resides at 3937 East Bautista Road, Gilbert, AZ 85297 (?Br
February 11, 2011	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2011 ONCOLOGIX TECH, INC. (Name of Small Business Issuer as Specified in Its Charter) Nevada 0-15482 & #160; 86-1006416 (State or other jurisdiction of (Commission File Number) &#
February 4, 2011	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [X] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [ ] Definitive P
January 14, 2011	10-Q	U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended November 30, 2010. o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission File Number 0-15482 ONCOLOGIX TECH, INC. (Name o
December 16, 2010	EX-99	Oncologix Tech, Inc WORKING CAPITAL NOTE EXHIBIT 99 Oncologix Tech, Inc WORKING CAPITAL NOTE $20,000 Phoenix, Arizona December 16, 2010 FOR VALUE RECEIVED, the undersigned, Oncologix Tech, Inc, a corporation duly formed and validly existing under the laws of the State of Nevada (the ?Borrower?), promises to pay to the order of Anthony Silverman(herein called the ?Lender?), thirty days from the date shown above, the principal sum of Twenty Thousand DOLLARS ($20,000).
December 16, 2010	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events 8-K 1 oncologix8k121610.htm PERIOD ENDED 12-16-10 U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2010 ONCOLOGIX TECH, INC. (Name of Small Business Issuer as Specified in Its Charter) Nevada 0-15482 86-1006416 (State or other j
November 29, 2010	10-K	U. S. SECURITIES AND EXCHANGE COMMISSION U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x Annual report under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended August 31, 2010 o Transition report under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 0-15482 ONCOLOGIX TECH, INC. (Name of small bus
November 29, 2010	EX-21	Subsidiaries of Oncologix Tech, Inc. Subsidiaries of Registrant Exhibit 21 Subsidiaries of Oncologix Tech, Inc. Subsidiaries of Registrant Subsidiary State of Incorporation or Jurisdiction Percent of Ownership of BestNet Communications Corp. Oncologix Corporation Nevada 100% International Environment Corporation Delaware 100% Interpretel (Canada) Inc. Province of Ontario 100% Interpretel, Inc. Arizona 100% Telplex International Arizona 100%
November 29, 2010	EX-99	Consent of Independent Registered Public Accounting Firm EXHIBIT 99 Consent of Independent Registered Public Accounting Firm Oncologix Tech, Inc.
September 14, 2010	8-K	Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant 8-K 1 oncologix8k090910.htm 8K DATED 00-0910 U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2010 ONCOLOGIX TECH, INC. (Name of Small Business Issuer as Specified in Its Charter) Nevada 0-15482 86-1006416 (State or other jurisd
September 14, 2010	EX-16.1	PCAOB Registered, Members of AACPA, CPCAF and UACPA & #160; EXHIBIT 16.1 CHISHOLM, BIERWOLF, NILSON & MORRILL, LLC Certified Public Accountants Phone (801) 292-8756 ? Fax (801) 292-8809 ? wwwcbnm.cpa.com Nephi J. Bierwolf Troy F. Nilson Douglas W. Morrill September 13, 2010 Office of the Chief Accountant Securities and Exchange Commission 450 West Fifth Street N.W. Washington DC 20549 Ladies and Gentlemen, We have read the statements about our firm
July 9, 2010	10-Q	U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended May 31, 2010. o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT 0F 1934 For the transition period from to . Commission File Number 0-15482 ONCOLOGIX TECH, INC. (Name of Smal
May 21, 2010	10-Q	U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended February 28, 2010. o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission File Number 0-15482 ONCOLOGIX TECH, INC. (Name o
May 18, 2010	8-K	Other Events 8-K 1 oncologix8k051710.htm PERIOD ENDED 05-17-10 U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2010 ONCOLOGIX TECH, INC. (Name of Small Business Issuer as Specified in Its Charter) Nevada 0-15482 86-1006416 (State or other jurisd
May 13, 2010	10-Q	U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended November 30, 2009. o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission File Number 0-15482 ONCOLOGIX TECH, INC. (Name o
April 1, 2010	8-K	Other Events U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2010 ONCOLOGIX TECH, INC. (Name of Small Business Issuer as Specified in Its Charter) Nevada 0-15482 86-1006416 (State or other jurisdiction of (Commission File Number) (I.R.S. Employ
August 25, 2004	SC 13D/A	Signature UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 7)* BESTNET COMMUNICATIONS CORP (Name of Issuer) Common Stock, $.001 Par Value (Title of Class of Securities) 08659K107 (CUSIP Number) Anthony Silverman 7305 E. Del Acero Drive Scottsdale, AZ 85258 (480) 657-7083 (Name, Address and Telephone Number of Person
June 2, 2004	SC 13D/A	Signature UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0145 Washington, D.
January 9, 2004	SC 13D/A	Signature UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* BESTNET COMMUNICATIONS CORP (Name of Issuer) Common Stock, $.001 Par Value (Title of Class of Securities) 08659K107 (CUSIP Number) Anthony Silverman 7305 E. Del Acero Drive Scottsdale, AZ 85258 (480) 657-7083 (Name, Address and Telephone Number of Person
December 1, 2003	EX-99.1	RE: Terms for Convertible Promissory Note Extension EX-99.1 3 c81359exv99w1.htm LETTER AGREEMENT November 14, 2003 To: Mr. Jerry Peterson From: Robert A. Blanchard, BestNet Communications Corp. RE: Terms for Convertible Promissory Note Extension Dear Jerry: This letter is to confirm and document our discussion regarding revised terms we are pleased to offer you for a one-year extension of your Convertible Promissory Note face value of $200,000 USD
December 1, 2003	SC 13D	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* OMB APPROVAL OMB Number: 3235-0145 Expires: December 31, 2005 Estimated average burden hours per response 11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
October 28, 2003	SC 13D/A	Signature SC 13D/A 1 a03-44271sc13da.htm SC 13D/A SEC 1746 (11-02) Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0145 Washington, D.C. 20549 Expires: December 31, 2005 SCHEDULE 13D Estimated av
October 17, 2003	SC 13D/A	Signature SEC 1746 (11-02) Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
September 26, 2003	SC 13D/A	Signature SC 13D/A 1 a03-36811sc13da.htm SC 13D/A SEC 1746 (11-02) Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0145 Washington, D.C. 20549 Expires: December 31, 2005 SCHEDULE 13D Estimated av
September 2, 2003	SC 13D/A	Signature SC 13D/A 1 a03-30751sc13da.htm SC 13D/A SEC 1746 (11-02) Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0145 Washington, D.C. 20549 Expires: December 31, 2005 SCHEDULE 13D Estimated av
January 16, 2003	4	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act OMB APPROVAL OMB Number: 3235-0287 Expires: January 31, 2005 Estimated average burden hours per response.
January 14, 2003	4	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act OMB APPROVAL OMB Number: 3235-0287 Expires: January 31, 2005 Estimated average burden hours per response.
January 10, 2003	4	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act OMB APPROVAL OMB Number: 3235-0287 Expires: January 31, 2005 Estimated average burden hours per response.
January 9, 2003	4	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act OMB APPROVAL OMB Number: 3235-0287 Expires: January 31, 2005 Estimated average burden hours per response.
January 3, 2003	4	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act OMB APPROVAL OMB Number: 3235-0287 Expires: January 31, 2005 Estimated average burden hours per response.
January 2, 2003	4	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act OMB APPROVAL OMB Number: 3235-0287 Expires: January 31, 2005 Estimated average burden hours per response.
December 24, 2002	4	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act OMB APPROVAL OMB Number: 3235-0287 Expires: January 31, 2005 Estimated average burden hours per response.
December 23, 2002	4	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act OMB APPROVAL OMB Number: 3235-0287 Expires: January 31, 2005 Estimated average burden hours per response.
December 19, 2002	4	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act OMB APPROVAL OMB Number: 3235-0287 Expires: January 31, 2005 Estimated average burden hours per response.
December 18, 2002	4	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act OMB APPROVAL OMB Number: 3235-0287 Expires: January 31, 2005 Estimated average burden hours per response.
December 16, 2002	4	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act OMB APPROVAL OMB Number: 3235-0287 Expires: January 31, 2005 Estimated average burden hours per response.
December 11, 2002	4	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Ac OMB APPROVAL OMB Number: 3235-0287 Expires: January 31, 2005 Estimated average burden hours per response.
December 9, 2002	4	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act OMB APPROVAL OMB Number: 3235-0287 Expires: January 31, 2005 Estimated average burden hours per response.
December 3, 2002	EX-24	POWER OF ATTORNEY POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints Erika Chow as the undersigned’s true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned’s capacity as a beneficial owner of the securities of BestNet Communications Inc.
December 3, 2002	4	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act OMB APPROVAL OMB Number: 3235-0287 Expires: January 31, 2005 Estimated average burden hours per response.

OCLG / Oncologix Tech, Inc. - SEC-arkiveringar, Årsredovisning, Fullmaktsutlåtande

Grundläggande statistik

SEC Filings

SEC Filings (Chronological Order)